Comparative Pharmacology
Head-to-head clinical analysis: GRIS PEG versus HALOTEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GRIS PEG versus HALOTEX.
GRIS-PEG vs HALOTEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Griseofulvin binds to and disrupts microtubule function by interfering with the polymerization of tubulin, thereby inhibiting fungal cell mitosis and nucleic acid synthesis.
Halotex (haloprogin) is a topical antifungal agent that disrupts fungal cell membrane permeability and inhibits ergosterol synthesis, leading to cell death.
For tinea capitis and other dermatophyte infections: 500 mg oral daily as a single dose or in divided doses. For more severe infections, up to 1 g daily in divided doses.
Apply topically twice daily for 2-4 weeks; tinea pedis may require up to 6 weeks.
None Documented
None Documented
Terminal elimination half-life 14-24 hours. With continuous therapy, time to steady-state is ~3-5 days.
Not well characterized; estimated terminal half-life approximately 24-48 hours based on limited data.
Primarily renal (as glucuronide conjugates): ~80%; fecal/biliary: ~10-15%; unchanged drug <1%.
Primarily fecal (biliary) as unchanged drug and metabolites; negligible renal excretion (<1%).
Category C
Category C
Antifungal
Antifungal